Kratochwil, C., Apostolidis, L., Rathke, H., Apostolidis, C., Bicu, F., Bruchertseifer, F., . . . Morgenstern, A. (2021). Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. European journal of nuclear medicine, 49(1), . https://doi.org/10.1007/s00259-021-05474-1
Chicago-Zitierstil (17. Ausg.)Kratochwil, Clemens, et al. "Dosing 225Ac-DOTATOC in Patients with Somatostatin-receptor-positive Solid Tumors: 5-year Follow-up of Hematological and Renal Toxicity." European Journal of Nuclear Medicine 49, no. 1 (2021). https://doi.org/10.1007/s00259-021-05474-1.
MLA-Zitierstil (9. Ausg.)Kratochwil, Clemens, et al. "Dosing 225Ac-DOTATOC in Patients with Somatostatin-receptor-positive Solid Tumors: 5-year Follow-up of Hematological and Renal Toxicity." European Journal of Nuclear Medicine, vol. 49, no. 1, 2021, https://doi.org/10.1007/s00259-021-05474-1.